Blinded NO Treatment Received Nomed


Combined with:

Aliskiren
Blinded Aliskiren Ali+Tab+CF
Blinded Enalapril Comp-Ena+
Blinded Placebo Comp-Pla+
Comparator Enalapril

Indications and Reactions:

Role Indications Reactions
Primary
Pancreatic Neuroendocrine Tumour 22.2%
Rash 13.9%
Cystic Fibrosis 8.3%
Rhinitis Allergic 8.3%
Gastrinoma 5.6%
Pancreatitis Chronic 5.6%
Pyrexia 5.6%
Back Pain 2.8%
Benign Prostatic Hyperplasia 2.8%
Bronchial Disorder 2.8%
Constipation 2.8%
Dry Skin 2.8%
Headache 2.8%
Hepatic Function Abnormal 2.8%
Hypertension 2.8%
Insomnia 2.8%
Onychomycosis 2.8%
Reflux Oesophagitis 2.8%
Pyrexia 66.7%
Vomiting 33.3%
Secondary
Cardiac Failure 37.0%
Carcinoid Tumour 10.4%
Glucose Tolerance Impaired 6.2%
Pancreatic Neuroendocrine Tumour 6.0%
Hypertension 5.5%
Cardiac Failure Chronic 5.1%
Dementia Alzheimer's Type 4.1%
Cardiovascular Disorder 3.8%
Breast Cancer 3.0%
Diabetes Mellitus 2.5%
Cardiac Failure Congestive 2.4%
Coronary Artery Disease 2.4%
Chronic Obstructive Pulmonary Disease 1.6%
Constipation 1.6%
Hepatic Neoplasm Malignant 1.6%
Type 2 Diabetes Mellitus 1.5%
Rash 1.4%
Pain 1.3%
Rhinitis Allergic 1.3%
Gout 1.2%
Vomiting 18.4%
Tinnitus 6.6%
Pyrexia 5.7%
Vertigo 5.7%
Syncope 4.9%
Weight Decreased 4.9%
Dyspnoea 4.6%
Renal Impairment 4.6%
Ventricular Extrasystoles 4.6%
Urine Output Decreased 4.3%
White Blood Cell Count Increased 4.3%
Tooth Extraction 4.0%
Urinary Tract Infection 3.7%
Hypotension 3.4%
Pneumonia 3.4%
Pulmonary Oedema 3.4%
Renal Failure Acute 3.4%
Ventricular Tachycardia 3.4%
Renal Failure 3.2%
Ventricular Dysfunction 3.2%
Concomitant
Cardiac Failure 57.1%
Colitis Ulcerative 21.4%
Arrhythmia 7.1%
Hyperuricaemia 7.1%
Insomnia 7.1%
Vomiting 100.0%

Drug Data